



(11) **EP 2 421 552 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 38/39 ^(2006.01) **G01N 33/567** ^(2006.01)
G01N 33/53 ^(2006.01) **A61P 11/06** ^(2006.01)
A61P 37/02 ^(2006.01)

(48) Corrigendum issued on:
25.01.2017 Bulletin 2017/04

(86) International application number:
PCT/US2010/032007

(45) Date of publication and mention
of the grant of the patent:
14.12.2016 Bulletin 2016/50

(87) International publication number:
WO 2010/124058 (28.10.2010 Gazette 2010/43)

(21) Application number: **10716439.4**

(22) Date of filing: **22.04.2010**

(54) **COLLAGEN V FOR USE IN THE TREATMENT OF ASTHMA**

COLLAGEN V FÜR DIE BEHANDLUNG VON ASTHMA

COLLAGEN V POUR LE TRAITEMENT DE L'ASTHME

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK SM TR

(30) Priority: **22.04.2009 US 171705 P**
02.12.2009 US 266048 P

(43) Date of publication of application:
29.02.2012 Bulletin 2012/09

(73) Proprietor: **Indiana University Research and**
Technology
Corporation
Indianapolis, IN 46202 (US)

(72) Inventor: **WILKES, David, S.**
Indianapolis
IN 46202 (US)

(74) Representative: **Schiweck, Weinzierl & Koch**
European Patent Attorneys
Landsberger Straße 98
80339 München (DE)

(56) References cited:
WO-A1-2007/120947

- **JEFFERY P K: "Remodeling in asthma and chronic obstructive lung disease." AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 15 NOV 2001 LNKD-PUBMED:11734464, vol. 164, no. 10 Pt 2, 15 November 2001 (2001-11-15), pages S28-S38, XP002602516 ISSN: 1073-449X**
- **VIGNOLA ET AL: "Tissue remodeling as a feature of persistent asthma" JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY, INC, US LNKD- DOI:10.1067/MAI.2000.107195, vol. 105, no. 6, 1 June 2000 (2000-06-01), pages 1041-1053, XP005687327 ISSN: 0091-6749**
- **PALMANS E ET AL: "Repeated allergen exposure changes collagen composition in airways of sensitised Brown Norway rats." THE EUROPEAN RESPIRATORY JOURNAL : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR CLINICAL RESPIRATORY PHYSIOLOGY AUG 2002 LNKD-PUBMED:12212956, vol. 20, no. 2, August 2002 (2002-08), pages 280-285, XP002602517 ISSN: 0903-1936**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 421 552 B8

专利名称(译)	胶原蛋白v用于治疗哮喘		
公开(公告)号	EP2421552B8	公开(公告)日	2017-01-25
申请号	EP2010716439	申请日	2010-04-22
[标]申请(专利权)人(译)	印第安纳UNIV RES TECH		
申请(专利权)人(译)	印第安纳大学研究与科技股份有限公司		
当前申请(专利权)人(译)	印第安纳大学研究与科技股份有限公司		
[标]发明人	WILKES DAVID S		
发明人	WILKES, DAVID, S.		
IPC分类号	A61K38/39 G01N33/567 G01N33/53 A61P11/06 A61P37/02		
CPC分类号	A61K38/39 G01N33/6854 G01N2333/78 G01N2800/122 G01N2800/50 G01N2800/52 G01N2800/56 A61P11/00 A61P11/06 A61P11/08 A61K9/0019 A61K9/0053 A61K9/0073 A61K39/0008		
优先权	61/171705 2009-04-22 US 61/266048 2009-12-02 US		
其他公开文献	EP2421552A1 EP2421552B1		
外部链接	Espacenet		

摘要(译)

本发明提供了用于治疗或预防包括COPD和哮喘的肺部疾病的化合物和方法。特别地，本发明提供了包含V型胶原蛋白或其耐受性片段的化合物，用于治疗COPD和哮喘。